Consolidated Financial Results for the Six Months (First Half) Ended September 30, 2026 [IFRS]

(Abridged)

November 4, 2026

Listed company: M3, Inc.
Listing: Tokyo Stock Exchange
Securities code: 2413
URL: https://corporate.m3.com/en/
Representative: Itaru Tanimura, Representative Director
Contact: Hirofumi Oba, Corporate Officer
Tel: +81-3-6229-8900
Scheduled date to file first-half securities report: November 13, 2026
Scheduled date to commence dividend payments: -
Preparation of supplementary materials on financial results: Yes
Holding of financial results briefing: Yes (for analysts and institutional investors)

(Amounts are rounded to the nearest million yen.)

1. Consolidated Financial Results for the Six Months (First Half) Ended September 30, 2026 (from April 1, 2026 to September 30, 2026)

(1) Consolidated Operating Results (Cumulative)

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit		Profit attributable to owners of the parent	
First Half ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2026	181,853	6.4	36,335	1.0	36,620	(0.2)	22,623	(10.7)	19,997	(11.9)
September 30, 2025	170,885	36.9	35,992	24.2	36,681	26.2	25,320	29.3	22,711	31.3

	Total comprehensive income		Basic earnings per share	Diluted earnings per share
First Half ended	Millions of yen	%	Yen	Yen
September 30, 2026	19,044	(32.0)	29.98	29.97
September 30, 2025	27,999	114.6	33.47	33.46

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of the parent	Ratio of equity attributable to owners of the parent to total assets	Equity per share attributable to owners of the parent
As of	Millions of yen	Millions of yen	Millions of yen	%	Yen
September 30, 2026	658,406	445,262	406,691	61.8	608.43
March 31, 2026	637,396	446,648	408,217	64.0	608.98

2. Dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal Year ended March 31, 2026	–	0.00	–	22.00	22.00
Fiscal Year ending March 31, 2027 (Actual)	–	0.00			
Fiscal Year ending March 31, 2027 (Forecast)			–	–	–

Notes:
1. Amendments to forecasts of dividends recently announced: None
2. Dividend forecast for the fiscal year ending March 31, 2027 is currently undetermined. It is to be determined after consideration of capital needs and condition of cash flow hereafter.

3. Consolidated Financial Results Forecasts for the Fiscal Year Ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes compared to the previous fiscal year.)

	Revenue		Operating profit		Profit before tax		Profit		Profit attributable to owners of the parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal Year ending March 31, 2027	400,000	13.8	80,000	8.8	81,000	6.2	56,000	3.6	53,000	7.9	78.29

Note: Amendments to forecasts of financial results recently announced: None

Notes

(1) Significant changes in the scope of consolidation during the period: None

(2) Changes in accounting policies and accounting estimates
- (i) Changes in accounting policies required by IFRS: None
- (ii) Changes in accounting policies other than item (i) above: None
- (iii) Changes in accounting estimates: None

(3) Number of shares issued (ordinary shares)

(i) Total number of shares issued at the end of the period (including treasury shares)	
As of September 30, 2026	679,128,200 shares
As of March 31, 2026	679,120,300 shares
(ii) Number of treasury shares at the end of the period	
As of September 30, 2026	13,671,139 shares
As of March 31, 2026	11,695,137 shares
(iii) Average number of shares outstanding during the period	
First Half ended September 30, 2026	667,118,584 shares
First Half ended September 30, 2025	678,474,600 shares

• Review of this financial report by certified public accountants or an audit firm: None

• Proper use of financial results forecasts and other special matters

(1) Disclaimer about forward-looking statements

The forward-looking statements herein are based on information available to the Company and on certain assumptions deemed to be reasonable at the date of publication of this document. They are not intended as the Company's commitment to achieve such forecasts, and actual results may differ significantly due to various factors.

(2) Supplementary materials on financial results

Supplementary materials on financial results will be posted on our website on Wednesday, November 4, 2026.

1. Overview of Financial Results, etc.

(1) Overview of Financial Results for the First Half Ended September 30, 2026

In Japan, we provide various services designed for healthcare professionals, centered on our website at m3.com with a membership of more than 350,000 physicians.

In Medical Platform segment, we offer a wide menu of services on the platform at m3.com, catering to various agendas and purposes of our clients. The services include MR-kun family services, which allow its registered physicians to proactively receive continuous and frequent information, marketing research services leveraging our panel of member healthcare professionals, and marketing support services for pharmaceutical companies to resolve fundamental drug-related challenges by utilizing the synergy of the M3 Group's diverse data assets and technologies including AI. In addition, our group companies provide a variety of services for medical institutions, including AI-enabled electronic health records (EHR), consultation support system, and a platform that allows for access to various medical AI centered on diagnostic imaging support, as well as external business succession support services for private practitioners using the panel of member physicians of m3.com. In other areas, we provide employee benefits services through EWEL,Inc., our subsidiary acquired in April 2025, as part of the White Jack Project, aimed at maintaining people's health from the pre-onset stage. We also offer digital transformation (DX) support for care facilities as well as healthcare and nursing care collaboration services, mainly through WISEMAN Co., Ltd., our new subsidiary acquired in July 2026.

In Evidence Solution segment, our group companies operate businesses serving as the following organizations: CRO that supports clinical development operations and large-scale clinical research; SMO that supports the management and operations of overall activities at clinical trial sites; and PRO that provides support for recruiting participants and carrying out peripheral operations necessary to conduct clinical development and clinical research.

In Career Solution segment, M3 Career, Inc. primarily provides job search and placement support services to physicians and pharmacists.

Site Solution segment provides services that assist medical institutions with their operations.

Patient Solution segment provides patient support services targeting hospitalized patients, nursing facility users, and so forth through offerings including "CS (Care Support) Set."

It also provides consumer-facing services, such as AskDoctors at <https://www.AskDoctors.jp/> (available in Japanese only). On this website, the member physicians of m3.com will answer questions from public users about health and diseases. Furthermore, M3 Education, Inc. provides medical and welfare professional education such as preparatory services for national examinations.

The M3 Group operates websites for healthcare professionals and has panels of physicians around the world, including Japan, the U.S., Europe, China, and South Korea, and the total number of healthcare professionals who have signed up for the websites and/or participated in the panels is now more than 7 million. Overseas segment provides global marketing research services using the panels of physicians, and it also offers services for pharmaceutical companies, career-related services focused on physicians, and others, primarily in the U.S. and Europe. Additionally, our offerings include clinical trial support services in North America, pharmaceutical database services in France, Germany, and Spain through the VIDAL Group, and the provision of SaaS-based EMR system "Weda" and other software for clinics primarily in France. We steadily expand business in other regions with a focus on Asia, especially India and South Korea, as well.

Consolidated financial results for the first half ended September 30, 2026 are as below.

(Millions of yen, unless otherwise stated)

	First Half ended September 30, 2025 (April 1, 2025 to September 30, 2025)	First Half ended September 30, 2026 (April 1, 2026 to September 30, 2026)	Year-on-year change		(Reference) Fiscal Year ended March 31, 2026 (April 1, 2025 to March 31, 2026)
Revenue	170,885	181,853	+10,968	+6.4%	351,363
Operating profit	35,992	36,335	+343	+1.0%	73,547
Profit before tax	36,681	36,620	(61)	(0.2%)	76,276
Profit	25,320	22,623	(2,697)	(10.7%)	54,046

Consolidated financial results by segment

(Millions of yen, unless otherwise stated)

		First Half ended September 30, 2025 (April 1, 2025 to September 30, 2025)	First Half ended September 30, 2026 (April 1, 2026 to September 30, 2026)	Year-on-year change	
Medical Platform	Segment revenue	51,977	54,384	+2,407	+4.6%
	Segment profit (loss)	17,870	18,487	+617	+3.5%
Evidence Solution	Segment revenue	12,180	11,713	(467)	(3.8%)
	Segment profit (loss)	2,331	1,973	(358)	(15.3%)
Career Solution	Segment revenue	13,175	12,686	(489)	(3.7%)
	Segment profit (loss)	4,343	4,438	+95	+2.2%
Site Solution	Segment revenue	26,291	28,735	+2,444	+9.3%
	Segment profit (loss)	1,694	930	(764)	(45.1%)
Patient Solution	Segment revenue	27,352	30,229	+2,877	+10.5%
	Segment profit (loss)	1,054	2,011	+956	+90.7%
Overseas	Segment revenue	41,063	45,447	+4,384	+10.7%
	Segment profit (loss)	8,925	9,854	+929	+10.4%
Other Emerging Businesses	Segment revenue	1,064	1,033	(31)	(2.9%)
	Segment profit (loss)	578	304	(274)	(47.4%)
Adjustment	Segment revenue	(2,216)	(2,373)	―	―
	Segment profit (loss)	(804)	(1,661)	―	―
Total	Revenue	170,885	181,853	+10,968	+6.4%
	Operating profit (loss)	35,992	36,335	+343	+1.0%

1) Medical Platform

Segment revenue amounted to 54,384 million yen, up 4.6% year on year. This is attributable to the contribution from the acquisition and subsequent consolidation of WISEMAN Co., Ltd. in July 2026 and the steady growth in businesses such as DX support for medical practices including the provision of EHR. Segment profit amounted to 18,487 million yen, up 3.5% year on year. This is attributable to the expansion of DX support for medical practices and the reversal of an impairment loss in the support business for medical institutions, partially offset by a decline in revenue from the high-margin pharmaceutical marketing support business.

2) Evidence Solution

Segment revenue amounted to 11,713 million yen, down 3.8% year on year, with segment profit of 1,973 million yen, down 15.3% year on year. This is attributable to the absence of the contribution from relatively high-margin projects and large-scale projects recorded in the same period of the previous fiscal year.

3) Career Solution

Segment revenue amounted to 12,686 million yen, down 3.7% year on year. This is attributable to a decline in revenue from job search and placement support services, mainly temporary staffing services for pharmacists. Segment profit amounted to 4,438 million yen, up 2.2% year on year, mainly due to the improvement in revenue mix.

4) Site Solution

Segment revenue amounted to 28,735 million yen, up 9.3% year on year. This is attributable to the steady growth across businesses, particularly in the domestic medical institution business and the hospice business. Segment profit amounted to 930 million yen, down 45.1% year on year. This is mainly attributable to a decline in revenue per patient due to the medical fee revisions in the hospice business, as well as an increase in upfront investments for new facility openings in the overseas medical institution business and the in-home nursing business.

5) Patient Solution

Segment revenue amounted to 30,229 million yen, up 10.5% year on year, with segment profit of 2,011 million yen, up 90.7% year on year. This is mainly attributable to the growing user base driven by new contracts for CS Set, the change in accounting treatment for original patient gowns from the fourth quarter of the previous fiscal year, and the recognition of a non-recurring investment-related gain.

6) Overseas

Segment revenue amounted to 45,447 million yen, up 10.7% year on year, with segment profit of 9,854 million yen, up 10.4% year on year. This is attributable to the revenue growth across regions driven by the positive foreign exchange impact from the year-on-year trend of yen depreciation and the improvement in revenue mix, partially offset by the impact of proactive upfront investments.

7) Other Emerging Businesses

Segment revenue amounted to 1,033 million yen, down 2.9% year on year, with segment profit of 304 million yen, down 47.4% year on year.

Combining all of the above, revenue of the M3 Group for the first half ended September 30, 2026 amounted to 181,853 million yen, up 6.4% year on year, with operating profit of 36,335 million yen, up 1.0% year on year, profit before tax of 36,620 million yen, down 0.2% year on year, and profit of 22,623 million yen, down 10.7% year on year.

Disclaimer: This document is a translation of the original Japanese version. The original Japanese version was prepared and disclosed by the Company in accordance with International Financial Reporting Standards. This document does not contain or constitute any guarantee and the Company will not compensate for any losses or damages arising from interpretations or actions taken based on this document. In the case of any discrepancies between the Japanese original and this document, the Japanese original is assumed to be correct.